EARLY BIRD Black Friday 2024 is HERE!

We’re making Black Friday EVEN BETTER with a never before offered EARLY BIRD rate💗 10 Spots total First-come, first-served Offer disappears when all spots are taken (or by Nov 28, 2024 midnight ET) This is the perfect option for the person wanting personalized, private support in a low-cost/low, time-commitment option OR the person with all her dream results who wants quarterly private check-ins for maintenance support: FOUR private calls (1 call per quarter starts Jan 1, 2025, ends Nov 29, 2025) Value

Read the full article here

Source: www.yourpathinfocus.com

Categories: Hem/Oncs, General Medicine News

Tweets with this article

Christina Arnold, MD

Make 2025 ENTIRELY better starting right now with this one decision. Get your spot here: https://t.co/xzEEhSgpKc

Osmoregulation of thirst and vasopressin secretion in human subjects: effect of various solutes – PubMed

Various hypertonic solutions were infused in healthy human volunteers to determine their effect on thirst and vasopressin secretion. Hypertonic saline and mannitol produced prompt and…

Tony Breu November 28, 2024

Thirst – PubMed

Our bodies are mostly water, and this water is constantly being lost through evaporative and other means. Thus the evolution of robust mechanisms for finding…

Tony Breu November 28, 2024

Current knowledge of vertebral osteomyelitis: a review

European Journal of Clinical Microbiology & Infectious Diseases – As life expectancy increases worldwide, the elderly population in every country is growing in both the…

Ramiro Esparza November 28, 2024

Immunotherapy for Early-Stage Triple-Negative Breast Cancer | NEJM

Early-stage triple-negative breast cancers, which lack expression of three proteins (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2), have long been defined…

Hal Burstein, MD November 28, 2024

“Target Trial Emulation” for Observational Studies — Potential and Pitfalls | NEJM

To improve the quality of observational studies, target trial emulation requires careful specification of design elements, analytic methods for addressing confounding, and reporting of sensitivity…

Gary Lyman November 28, 2024

Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies

This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and assessing…

Adam J. Schoenfeld November 28, 2024

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | NEJM

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition…

Gil Morgan November 28, 2024

Paper: Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)

Program: Oral and Poster Abstracts Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Clinical trials, MPN, Drug development,…

Naveen Pemmaraju, MD November 27, 2024

Immunotherapy for Early-Stage Triple-Negative Breast Cancer | NEJM

Early-stage triple-negative breast cancers, which lack expression of three proteins (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2), have long been defined…

Hal Burstein, MD November 27, 2024

The Duffy Null Phenotype — Addressing a Source of Discrimination in Cancer Care | NEJM

Cancer research and care practices that adversely affect people with the Duffy null phenotype are an underrecognized and widespread source of discrimination against people of…

Lauren Merz November 27, 2024

Related Articles